parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in late spermatids	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 19	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 10352

TADA2A in microglia, braak-0.47 (p 0.204) → +0.61 (p 0.078)receipt 10360
TADA2A in dopamine neurons, braak+0.03 (p 0.947) → +0.11 (p 0.784)receipt 10361

receipt 10361: TADA2A in dopamine neurons, braak

power: full sample +0.09 (p 0.722, n 18), 95% CI -0.39 to +0.53. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.06 (p 0.814, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.09 (p 0.735, n 18). could be the mix.
skeptic: leave-one-out range -0.02 to +0.20, sign flips 3; without severely affected donors +0.09 (p 0.722, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TADA2A in dopamine neurons.

case closed: nothing better to follow up.

receipt 10360: TADA2A in microglia, braak

power: full sample -0.10 (p 0.696, n 18), 95% CI -0.54 to +0.39. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.10 (p 0.690, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.09 (p 0.728, n 18). could be the mix.
skeptic: leave-one-out range -0.20 to +0.02, sign flips 4; without severely affected donors -0.10 (p 0.696, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TADA2A in microglia.

case closed: nothing better to follow up.

loading the receipts